NuVasive's US procedure volumes stay slow in 2017, international revenue up: 5 things to know

Laura Dyrda -   Print  | Email

NuVasive expects 2017 revenue to hit $1.03 billion, in line with previously reported guidance with the lingering impact of Hurricane Maria factored in.

Here are five things to know:


1. NuVasive expects a 7 percent growth in 2017 full-year revenue, hitting $1.03 billion. The company expects fourth quarter revenue to be reported as $272 million, as U.S. procedure volumes remained "soft" in the aftermath of the 2017 hurricanes.


2. NuVasive expects the 2018 financial outlook to include the impact of its SafePassage acquisition, made in the fourth quarter of 2017. The acquisition is expected to bolster the NuVasive Clinical Services business and elevate the company as the largest provider of outsourced intraoperative neuromonitoring services.


3. Based on the expected impact of the U.S. tax reform in 2018, NuVasive expects to realize substantial tax savings with the corporate tax rate reduced from 35 percent to 21 percent. Prior to the reform, NuVasive's tax rate was expected to be around 33 percent on a non-GAAP basis in 2018.


4. NuVasive launched several new technologies in 2017 and accelerated growth across the board, with a 20 percent sales increase in the international markets for the fifth sequential quarter.


5. The company will provide a full 2018 financial outlook in mid-February.


More articles on orthopedic devices:
Medtronic, DePuy Synthes & more: 8 device company mergers, acquisitions & agreements
Arthrex begins headquarter expansion, to add 500+ jobs
23 spine devices receive FDA clearance in November 2017

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.